recent
occurr
human
infect
virul
avian
influenza
emerg
swine
origin
pandem
influenza
strain
spark
fear
ongo
pandem
novel
genet
charact
vaccin
remain
effect
public
health
strategi
prevent
antivir
drug
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
could
play
import
role
respons
earli
phase
pandem
avail
suffici
quantiti
howev
like
antivir
agent
emerg
influenza
virus
reduc
suscept
nai
inevit
treatment
date
strain
alter
suscept
nai
recov
approxim
immunocompet
adult
patient
pediatr
patient
addit
oseltamivirresist
influenza
pandem
virus
mutat
report
patient
oseltamivir
treatment
signific
advanc
molecular
biolog
human
genom
research
pave
way
host
new
genet
diagnost
test
includ
gene
sequenc
detect
identif
genotyp
organ
use
real
time
polymeras
chain
reaction
pcr
amplif
techniqu
multiplex
pcr
revers
line
blot
hybrid
rlb
ligas
chain
reaction
lcr
roll
circl
amplif
rca
microarray
sequenc
often
serv
gold
standard
detect
singl
nucleotid
polymorph
drug
resist
mutat
virusbacteri
type
howev
sequenc
cumbersom
expens
less
like
detect
low
preval
mutat
mutat
consist
less
total
popul
newer
altern
techniqu
real
time
pcr
rca
employ
establish
molecular
assay
posit
control
prerequisit
ascertain
specif
sensit
howev
mani
case
difficult
cumbersom
acquir
appropri
posit
control
thu
import
mention
although
commerci
oligonucleotid
synthesi
gener
long
oligonucleotid
mer
serv
suitabl
control
problem
oligonucleotid
length
exce
nucleobas
yield
desir
product
often
becom
limit
side
reaction
even
modest
ineffici
within
stepwis
chemic
reaction
larg
effect
final
yield
event
influenza
pandem
drug
resist
strain
transmiss
could
clinic
highli
signific
mean
sensit
specif
techniqu
requir
earli
clinic
relev
detect
howev
due
low
frequenc
natur
occur
resist
mutat
influenza
infect
patient
receiv
na
inhibitor
treatment
highli
pathogenet
natur
influenza
strain
technic
complex
time
consum
natur
gener
na
resist
strain
vitro
collect
known
resist
mutat
posit
control
challeng
therefor
approach
util
format
oligonucleotid
dimer
two
commerci
synthesis
long
singl
strand
dna
templat
base
gener
bp
doublestrand
artifici
dna
templat
contain
resist
mutat
innov
molecularli
feasibl
durabl
way
offer
signific
advantag
synthes
even
longer
doubl
strand
dna
templat
use
posit
control
templat
molecular
diagnost
present
studi
use
doubl
strand
artifici
dna
templat
known
genet
mutat
associ
influenza
drug
resist
posit
control
develop
ligas
chain
reaction
lcr
detect
na
inhibitor
drug
resist
mutat
patient
sampl
pcr
reaction
cycl
product
pair
synthet
long
oligo
run
agaros
gel
stain
ethidium
bromid
view
uv
light
dsdna
product
clearli
visual
size
bp
figur
demonstr
success
product
long
ds
dna
templat
synthet
oligo
pcr
product
pair
oligo
clone
posit
clone
sequenc
valid
presenc
desir
mutat
sequenc
align
care
compar
artifici
templat
refer
strain
expect
sequenc
ident
artifici
templat
design
carri
resist
mutat
tabl
standard
liner
templat
contain
resist
mutat
variou
level
prepar
mix
wildtyp
templat
templat
contain
resist
mutat
standard
templat
target
four
independ
probe
specif
recogn
resist
mutat
cycl
ligat
reaction
even
presenc
lowlevel
resist
mutat
could
detect
evid
format
specif
dsdna
molecul
bp
figur
although
sequenc
serv
gold
standard
detect
singl
nucleotid
polymorph
associ
drug
resist
mutat
organ
type
method
altern
techniqu
employ
one
impedi
techniqu
lack
avail
control
templat
carri
rare
mutant
variantsallel
relev
mutat
serv
posit
control
molecular
multiplex
pcr
assay
simultan
influenza
studi
exampl
sever
singl
nucleotid
mutat
known
associ
na
inhibitor
resist
mani
deriv
differ
vitro
cultur
current
natur
occur
nai
resist
appear
uncommon
strain
howev
event
influenza
pandem
use
nai
would
dramat
increas
thu
provid
greater
opportun
resist
emerg
spread
therefor
rapid
screen
mutat
would
great
benefit
patient
treatment
control
diseas
spread
avail
format
facilit
simultan
rapid
bulk
detect
drug
resist
mutat
abl
sourc
wildtyp
clinic
isol
influenza
known
resist
clinic
strain
unavail
given
highli
pathogen
avian
influenza
handl
facil
limit
access
influenza
rna
main
impedi
molecular
assay
develop
detect
drug
resist
mutat
thu
endeavor
creat
artifici
templat
contain
previous
identifi
singl
nucleotid
mutat
known
drug
resist
within
neuraminidas
gene
influenza
viru
address
issu
produc
long
synthet
oligo
contain
known
influenza
resist
mutat
show
effect
control
lcr
also
serv
templat
realtim
pcr
rca
use
fulli
synthet
oligonucleotid
posit
control
materi
describ
recent
howev
limit
length
oligonucleotid
gener
unabl
reach
base
mani
situat
instanc
case
drug
resist
mutat
nucleotid
substitut
often
scatter
within
target
genom
thu
requir
larger
fragment
standard
templat
took
novel
approach
creat
long
artifici
templat
take
advantag
primerdim
usual
consid
common
laboratori
problem
bind
two
long
artifici
synthes
oligo
gener
substrat
pcr
use
creat
long
doublestrand
dna
molecul
bp
current
diagnost
studi
especi
base
real
time
pcr
rca
bp
would
suffici
serv
templat
control
howev
possibl
use
multipl
long
oligo
synthes
even
longer
doublestrand
dna
full
length
import
gene
need
signific
advantag
similar
technolog
exist
current
signific
advantag
use
synthet
oligonucleotid
flexibl
approach
proven
use
laboratori
safe
artifici
templat
rel
cost
effect
simpl
effici
altern
difficult
acquir
materi
relat
infect
bioterror
agent
product
standard
templat
via
format
oligo
dimer
pcr
use
synthet
oligo
requir
use
viral
bacteri
strain
oligo
desir
sequenc
made
commerci
approach
may
potenti
produc
falseposit
product
due
contamin
therefor
caution
may
necessari
howev
problem
solv
introduct
exclus
restrict
endonucleas
digest
site
artifici
templat
would
allow
rapid
confirm
falseposit
result
certain
restrict
endonucleas
smai
bamhi
use
directli
pcr
buffer
without
buffer
exchang
thu
pcr
product
control
easili
rapidli
distinguish
test
sampl
addit
standard
artifici
templat
could
design
slightli
smaller
larger
size
would
allow
direct
visual
identif
contamin
synthet
control
overal
technolog
may
wide
rang
applic
may
revolution
molecular
diagnost
use
multiplex
assay
refer
strain
influenza
use
studi
genebank
access
number
respect
long
singlestrand
oligonucleotid
base
design
contain
wildtyp
templat
drug
resist
mutat
tabl
synthesi
oligonucleotid
page
purifi
sigmaaldrich
sydney
australia
pair
long
oligo
design
carri
complementari
sequenc
end
pmol
pair
oligo
incub
u
taq
dna
polymeras
promega
madison
usa
reaction
buffer
mm
mm
dntp
reaction
mix
incub
second
follow
second
second
cycl
reaction
end
product
run
agaros
gel
visual
uv
light
ethidium
bromid
stain
process
complementari
sequenc
locat
end
pair
oligo
would
form
dimer
presenc
dna
polymeras
dntp
oligo
would
extend
end
use
second
oligo
templat
figur
ensur
puriti
standard
templat
product
ligat
pgemt
easi
vector
system
ii
promega
madison
usa
transform
compet
escherichia
coli
cell
accord
manufactur
protocol
screen
gene
insert
perform
quick
lysi
e
coli
cell
minut
follow
pcr
use
cell
lysat
previous
describ
plasmid
dna
posit
clone
extract
use
qiaprep
spin
miniprep
kit
accord
manufactur
protocol
qiagen
melbourn
australia
insert
sequenc
use
appli
biosystem
bigdy
termin
chemistri
version
foster
citi
ca
usa
abi
prism
dna
sequenc
sequenc
identifi
use
fasta
program
group
access
biomanag
http
biomanagerinfo
liner
templat
contain
resist
wild
type
gener
pcr
amplif
plasmid
dna
follow
purif
use
millipor
pcr
purif
plate
millipor
billerica
usa
linear
pcr
product
quantit
use
spectrophotomet
dsdna
dna
copi
number
estim
dna
calcul
http
wwwurieduresearchgscresourcescndnahtml
copi
standard
templat
use
test
specif
lcr
system
lcr
probe
target
resist
templat
design
tabl
templat
target
four
lcr
probe
probe
end
phosphoryl
ligat
lcr
probe
standard
templat
carri
mix
standard
templat
lcr
probe
pfu
dna
ligas
stratagen
integr
scienc
cedar
creek
tx
usa
mm
trishcl
ph
mm
kcl
mm
igep
mm
ratp
mm
dtt
total
reaction
volum
multipl
cycl
ligat
conduct
valid
specif
probe
recogn
correspond
templat
reaction
condit
includ
one
cycl
min
denatur
dsdna
follow
cycl
min
ligat
final
product
run
tbe
gel
invitrogen
mount
waverley
vic
australia
visual
uv
light
ethidium
bromid
stain
nai
neuraminidas
inhibitor
pcr
polymeras
chain
reaction
rlb
revers
line
blot
hybrid
lcr
ligas
chain
reaction
rca
roll
circl
amplif
author
declar
compet
interest
bw
conceiv
design
conduct
studi
along
sequenc
search
data
analys
manuscript
write
ms
assist
assay
optim
clone
dna
sequenc
dd
ac
ns
provid
intellectu
input
manuscript
write
author
read
approv
manuscript
